Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 9/20 | 0.52 |
| ▸ | AKR1C2 | P52895 | 9/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.52 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.44 |
| ▸ | CDC42 | P60953 | 1/20 | 0.44 |
| ▸ | RAC1 | P63000 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL218395 | 0.94 | AKR1C3 (0.50) | AKR1C3AKR1C2PTGS1AKR1C1PTGS2 | |
| SCHEMBL5152798 | 0.87 | AKR1C3 (0.61) | AKR1C3AKR1C2PTGS1AKR1C1PTGS2 | |
| SCHEMBL219246 | 0.87 | AKR1C3 (0.47) | AKR1C3AKR1C2PTGS1AKR1C1PTGS2 | |
| SCHEMBL220331 | 0.85 | AKR1C3 (0.45) | AKR1C3AKR1C2PTGS1AKR1C1PTGS2 | |
| SCHEMBL219069 | 0.85 | AKR1C3 (0.53) | AKR1C3AKR1C2PTGS1AKR1C1PTGS2 | |
| SCHEMBL220109 | 0.80 | TDP1 (0.51) | AKR1C3AKR1C2PTGS1PTGS2CDC42 | |
| SCHEMBL5154741 | 0.78 | AKR1C3 (0.54) | AKR1C3AKR1C2PTGS1AKR1C1PTGS2 | |
| SCHEMBL221553 | 0.77 | AKR1C3 (0.62) | AKR1C3AKR1C2PTGS1AKR1C1PTGS2 | |
| SCHEMBL218529 | 0.77 | AKR1C3 (0.51) | AKR1C3AKR1C2PTGS1AKR1C1PTGS2 | |
| SCHEMBL5151710 | 0.77 | AKR1C3 (0.53) | AKR1C3AKR1C2PTGS1AKR1C1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304409-B2 | Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use | NICOX S.A. (FR) | 2012-11-06 | — | — | US | disclosed |
| US-8088762-B2 | Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use | NICOX S.A. (FR) | 2012-01-03 | — | — | US | disclosed |
| US-20110098253-A1 | Nitrosated Nonsteroidal Antiinflammatory Compounds, Compositions and Methods of Use | NICOX S.A. (IT) | 2011-04-28 | — | — | US | disclosed |
| US-7883714-B2 | (2R)-2,3-bis(nitrooxy)propyl(2S)-2(6-methoxy(2-naphthyl)propanoate, used for treating inflammation, pain and fever; gastrointestinal disorders; wound healing agents; preventing gastrointestinal, renal and/or respiratory toxicities; side effect reduction; kits | NICOX S.A. (FR) | 2011-02-08 | — | — | US | disclosed |
| US-20100137291-A1 | NITROSATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NICOX SA (FR) | 2010-06-03 | — | — | US | disclosed |
| US-20100093671-A1 | NITROSATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NICOX SA (FR) | 2010-04-15 | — | — | US | disclosed |
| US-20100093708-A1 | NITROSATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NICOX SA (FR) | 2010-04-15 | — | — | US | disclosed |
| US-7163958-B2 | Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use | NITROMED INC. (US) | 2007-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093708-A1 | NITROSATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NOS2, NOS1, NOS3 | AKR1C3 280/4885AKR1C2 465/4885PTGS1 4/4885 |
| US-20110098253-A1 | Nitrosated Nonsteroidal Antiinflammatory Compounds, Compositions and Methods of Use | NOS2, NOS1, NOS3 | AKR1C3 499/4885AKR1C2 843/4885PTGS1 4/4885 |
| US-20100093671-A1 | NITROSATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NOS2, NOS1, NOS3 | AKR1C3 280/4885AKR1C2 465/4885PTGS1 4/4885 |
| US-20100137291-A1 | NITROSATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NOS2, NOS1, NOS3 | AKR1C3 280/4885AKR1C2 465/4885PTGS1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.